{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:45:43Z","timestamp":1781135143955,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12325-022-02362-4","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:58:51Z","timestamp":1669301931000},"page":"1379-1392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Histology-Agnostic Drugs: A Paradigm Shift\u2014A Narrative Review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-0838","authenticated-orcid":false,"given":"Andr\u00e9","family":"Mansinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Miguel","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio Vaz","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"issue":"4","key":"2362_CR1","first-page":"177","volume":"32","author":"C Meldrum","year":"2011","unstructured":"Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev. 2011;32(4):177\u201395.","journal-title":"Clin Biochem Rev"},{"issue":"6","key":"2362_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1087057108319644","volume":"13","author":"LM Mayr","year":"2008","unstructured":"Mayr LM, Fuerst P. The future of high-throughput screening. J Biomol Screen. 2008;13(6):443\u20138.","journal-title":"J Biomol Screen"},{"issue":"3","key":"2362_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrd1035","volume":"2","author":"H Mario Geysen","year":"2003","unstructured":"Mario Geysen H, Schoenen F, Wagner D, Wagner R. Combinatorial compound libraries for drug discovery: an ongoing challenge. Nat Rev Drug Discov. 2003;2(3):222\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"2362_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00733","author":"W Cui","year":"2020","unstructured":"Cui W, Aouidate A, Wang S, et al. Discovering Anti-cancer drugs via computational methods. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00733.","journal-title":"Front Pharmacol"},{"key":"2362_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102019","volume":"86","author":"AM Tsimberidou","year":"2020","unstructured":"Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86: 102019.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2362_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455\u201367.","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"2362_CR7","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"34","key":"2362_CR8","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032\u20138.","journal-title":"J Clin Oncol"},{"issue":"7387","key":"2362_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100\u20133.","journal-title":"Nature"},{"issue":"17","key":"2362_CR10","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632\u201343.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"2362_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1200\/JCO.2018.36.15_suppl.101","volume":"36","author":"IE Krop","year":"2018","unstructured":"Krop IE, Jegede O, Grilley-Olson JE, et al. Results from molecular analysis for therapy choice (MATCH) arm I: taselisib for PIK3CA-mutated tumors. J Clin Oncol. 2018;36(15_suppl):101.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2362_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-019-0285-2","volume":"16","author":"NJ Curtin","year":"2019","unstructured":"Curtin NJ, Drew Y, Sharma-Saha S. Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. Nat Rev Clin Oncol. 2019;16(12):725\u20136.","journal-title":"Nat Rev Clin Oncol"},{"key":"2362_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conctc.2018.08.009","volume":"12","author":"A Hirakawa","year":"2018","unstructured":"Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: review and new trial designs. Contemp Clin Trials Commun. 2018;12:1\u20138.","journal-title":"Contemp Clin Trials Commun"},{"issue":"3","key":"2362_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/cancers13030583","volume":"13","author":"D Horgan","year":"2021","unstructured":"Horgan D, Ciliberto G, Conte P, et al. Bringing onco-innovation to Europe\u2019s healthcare systems: the potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine. Cancers (Basel). 2021;13(3):583.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2362_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"2362_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.2016.69.9751","volume":"35","author":"KM Cunanan","year":"2017","unstructured":"Cunanan KM, Gonen M, Shen R, et al. Basket trials in oncology: a trade-off between complexity and efficiency. J Clin Oncol. 2017;35(3):271\u20133.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2362_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-med-062016-050343","volume":"69","author":"JJ Tao","year":"2018","unstructured":"Tao JJ, Schram AM, Hyman DM. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med. 2018;69(1):319\u201331.","journal-title":"Annu Rev Med"},{"key":"2362_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102082","volume":"90","author":"C Dittrich","year":"2020","unstructured":"Dittrich C. Basket trials: from tumour gnostic to tumour agnostic drug development. Cancer Treat Rev. 2020;90: 102082.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"2362_CR19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.molonc.2014.06.002","volume":"8","author":"D Lacombe","year":"2014","unstructured":"Lacombe D, Burock S, Bogaerts J, et al. The dream and reality of histology agnostic cancer clinical trials. Mol Oncol. 2014;8(6):1057\u201363.","journal-title":"Mol Oncol"},{"key":"2362_CR20","unstructured":"Rodes Sanchez M, Henderson N, Steuten L. Bridging the gap: pathways for regulatory and health technology assessment of histology independent therapies. Consult. Reports 002290, Off. Heal. Econ. 2020."},{"issue":"11","key":"2362_CR21","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1158\/1078-0432.CCR-18-3694","volume":"25","author":"C Hierro","year":"2019","unstructured":"Hierro C, Matos I, Martin-Liberal J, et al. Agnostic-histology approval of new drugs in oncology: are we already there? Clin Cancer Res. 2019;25(11):3210\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2362_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"2362_CR23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"2362_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2362_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/0008-5472.CAN-07-3095","volume":"68","author":"NH Segal","year":"2008","unstructured":"Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008;68(3):889\u201392.","journal-title":"Cancer Res"},{"issue":"1","key":"2362_CR26","first-page":"33","volume":"10","author":"JR Eshleman","year":"1995","unstructured":"Eshleman JR, Lang EZ, Bowerfind GK, et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene. 1995;10(1):33\u20137.","journal-title":"Oncogene"},{"issue":"26","key":"2362_CR27","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"13","key":"2362_CR28","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753\u20138.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2362_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365.","journal-title":"Lancet Oncol"},{"key":"2362_CR30","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors. Accessed 02 Oct 2022."},{"issue":"1","key":"2362_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0092-8674(91)90419-Y","volume":"65","author":"R Klein","year":"1991","unstructured":"Klein R, Jing S, Nanduri V, et al. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65(1):189\u201397.","journal-title":"Cell"},{"issue":"23","key":"2362_CR32","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1158\/1078-0432.CCR-18-1156","volume":"24","author":"ES Kheder","year":"2018","unstructured":"Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24(23):5807\u201314.","journal-title":"Clin Cancer Res"},{"issue":"6056","key":"2362_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/319743a0","volume":"319","author":"D Martin-Zanca","year":"1986","unstructured":"Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319(6056):743\u20138.","journal-title":"Nature"},{"issue":"2","key":"2362_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000023","volume":"1","author":"A Amatu","year":"2016","unstructured":"Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2): e000023.","journal-title":"ESMO Open"},{"issue":"12","key":"2362_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731\u201347.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2362_CR36","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","volume":"5","author":"RC Doebele","year":"2015","unstructured":"Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5(10):1049\u201357.","journal-title":"Cancer Discov"},{"issue":"8","key":"2362_CR37","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med"},{"key":"2362_CR38","doi-asserted-by":"publisher","first-page":"v162","DOI":"10.1093\/annonc\/mdz244.007","volume":"30","author":"DM Hyman","year":"2019","unstructured":"Hyman DM, van Tilburg CM, Albert CM, et al. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol. 2019;30:v162\u20133.","journal-title":"Ann Oncol"},{"key":"2362_CR39","doi-asserted-by":"publisher","first-page":"vii133","DOI":"10.1093\/annonc\/mdy279.397","volume":"29","author":"UN Lassen","year":"2018","unstructured":"Lassen UN, Albert CM, Kummar S, et al. Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach. Ann Oncol. 2018;29:vii133.","journal-title":"Ann Oncol"},{"issue":"2","key":"2362_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21(2):271\u201382.","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"2362_CR41","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2020.38.15_suppl.3605","volume":"38","author":"CD Rolfo","year":"2020","unstructured":"Rolfo CD, De Braud FG, Doebele RC, et al. Efficacy and safety of entrectinib in patients (pts) with NTRK -fusion positive (NTRK-fp) solid tumors: an updated integrated analysis. J Clin Oncol. 2020;38(15_suppl):3605\u20133605.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2362_CR42","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","volume":"7","author":"A Drilon","year":"2017","unstructured":"Drilon A, Siena S, Ou S-HI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400\u20139.","journal-title":"Cancer Discov."},{"issue":"15_suppl","key":"2362_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.2020.38.15_suppl.107","volume":"38","author":"AV Desai","year":"2020","unstructured":"Desai AV, Robinson GW, Basu EM, et al. Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. J Clin Oncol. 2020;38(15_suppl):107\u2013107.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2362_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100087","volume":"6","author":"J Delgado","year":"2021","unstructured":"Delgado J, Pean E, Melchiorri D, et al. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearr. ESMO Open. 2021;6(2): 100087.","journal-title":"ESMO Open"},{"issue":"11","key":"2362_CR45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1200\/JCO.20.03025","volume":"39","author":"R Dziadziuszko","year":"2021","unstructured":"Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol. 2021;39(11):1253\u201363.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2362_CR46","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2019.37.15_suppl.3003","volume":"37","author":"M Fakih","year":"2019","unstructured":"Fakih M, O\u2019Neil B, Price TJ, et al. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRAS G12C inhibitor, in advanced solid tumors. J Clin Oncol. 2019;37(15_suppl):3003\u20133003.","journal-title":"J Clin Oncol"},{"key":"2362_CR47","doi-asserted-by":"publisher","first-page":"S1274","DOI":"10.1016\/j.annonc.2020.10.103","volume":"31","author":"JH Strickler","year":"2020","unstructured":"Strickler JH, Fakih M, Price TJ, et al. 83MO AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: results from the CodeBreaK100 phase I trial. Ann Oncol. 2020;31:S1274\u20135.","journal-title":"Ann Oncol"},{"issue":"8","key":"2362_CR48","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869\u201376.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"2362_CR49","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2018.36.15_suppl.102","volume":"36","author":"AE Drilon","year":"2018","unstructured":"Drilon AE, Subbiah V, Oxnard GR, et al. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. J Clin Oncol. 2018;36(15_suppl):102\u2013102.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2362_CR50","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","volume":"25","author":"S Jonna","year":"2019","unstructured":"Jonna S, Feldman RA, Swensen J, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25(16):4966\u201372.","journal-title":"Clin Cancer Res"},{"key":"2362_CR51","doi-asserted-by":"crossref","unstructured":"MCLA-128 Fights NRG1 Fusion\u2013Positive Cancers. Cancer Discov. 2019; 9(12):1636.2\u20131636.","DOI":"10.1158\/2159-8290.CD-NB2019-128"},{"issue":"9","key":"2362_CR52","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895\u2013902.","journal-title":"Ann Oncol"},{"key":"2362_CR53","doi-asserted-by":"publisher","first-page":"S1092","DOI":"10.1016\/j.annonc.2020.08.1323","volume":"31","author":"P Martin Romano","year":"2020","unstructured":"Martin Romano P, Mezquita L, Lacroix L, et al. 1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2020;31:S1092\u20133.","journal-title":"Ann Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02362-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02362-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02362-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:35:49Z","timestamp":1680518149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02362-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2362"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02362-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}